A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease

• Published in: Journal of the American College of Cardiology 2007-10, Vol.50 (14), p.1373-1380
• Main Authors: Schömig, Albert, MD, Dibra, Alban, MD, Windecker, Stephan, MD, Mehilli, Julinda, MD, Suárez de Lezo, José, MD, Kaiser, Christoph, MD, Park, Seung-Jung, MD, Goy, Jean-Jacque, MD, Lee, Jae-Hwan, MD, Di Lorenzo, Emilio, MD, Wu, Jinjin, MD, Jüni, Peter, MD, Pfisterer, Matthias E., MD, Meier, Bernhard, MD, Kastrati, Adnan, MD
• Format: Article
• Language: English
• Subjects: Aged; Blood Vessel Prosthesis; Cardiology; Cardiovascular; Comorbidity; Coronary Artery Disease - mortality; Coronary Artery Disease - therapy; Coronary Thrombosis - epidemiology; Coronary vessels; Drug Delivery Systems; Drug therapy; Global Health; Heart attacks; Humans; Immunosuppressive Agents - administration & dosage; Internal Medicine; Meta-analysis; Middle Aged; Myocardial Infarction - epidemiology; Outcome and Process Assessment (Health Care); Paclitaxel - administration & dosage; Randomized Controlled Trials as Topic; Recurrence; Sirolimus - administration & dosage; Stents; Stents - adverse effects; Survival Analysis; Treatment Outcome; Tubulin Modulators - administration & dosage
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2007.06.047

A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease Albert Schömig, Alban Dibra, Stephan Windecker, Julinda Mehilli, José Suárez de Lezo, Christoph Kaiser, Seung-Jung Park, Jean-Jacque Goy, Jae-Hwan Lee, Emilio Di Lorenzo, Jinjin Wu, Peter Jüni, Matthias E. Pfisterer, Bernhard Meier, Adnan Kastrati We performed a meta-analysis of 16 randomized trials of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) with a total number of 8,695 patients. Mean follow-up period ranged from 9 to 37 months. Compared with PES, SES significantly reduced the risk of reintervention (hazard ratio [HR] of 0.74; 95% confidence interval [CI] 0.63 to 0.87), and stent thrombosis (HR of 0.66; 95% CI 0.46 to 0.94), without significantly impacting on the risk of death (HR of 0.92; 95% CI 0.74 to 1.13), or myocardial infarction (HR of 0.84; 95% CI 0.69 to 1.03). Thus, SES are superior to PES in terms of a significant reduction of the risk of reintervention and stent thrombosis.